RE:RE:RE:WantingThere's so much variability in covid's effects on individuals based on their specific health circumstances that the margin of error for determining the efficacy of a treatment in their severe/critical condition category is so high that their primary endpoint results would have to be near irrefutable to say with any confidence that the treatment actually "works."
From a quick peek at the data, it looks like they were quite literally trying to turn some of these patients around at death's door. So, were they trying to set themselves up for failure or just way over-confident in their drug candidate?
Inconclusive results which failed to meet the primary endpoint due to poorly-designed patient selection criteria, coupled with managerial shenanigans surrounding the recently-settled shareholder derivative lawsuit resulting in the cancellation of 10s of millions of inappropriate, "self-dealing" options awards to management and directors...
Hard pass.
Pandora wrote: Not sure if anyone noticed because it is not on topic but CYDY came out with results of their 10 month Covid trial and the story was -- theresults did not meet necessary endpoints because th etrial had been structured incorrectly regarding age groups and also the numbers between placebo and Leronlimab groups. i.e. after ten months they recognize a complete screwup in the format?
Another case of small pharma being mucked up by the FDA or ??
Now they want them to start another trial and this is one of the most effective drugs for a covid therapeutic that has been found todate.